Fecal markers in the management of inflammatory bowel disease

References

• Canani RB, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40(7):547–553. [pii][published Online First: Epub Date]|.
   PubMedGoogle Scholar
• Leach ST, Day AS. S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease. Expert Rev Clin Immunol. 2006;2(3):471–480. [published Online First: Epub Date]|.
   PubMedGoogle Scholar
• Ramasundara M, Leach ST, Lemberg DA, et al. Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24(2):202–208. JGH5772 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Chong SK, Blackshaw AJ, Boyle S, et al. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut. 1985;26(1):55–59.
   PubMed Web of Science ®Google Scholar
• Price AB, Morson BC. Inflammatory bowel disease: the surgical pathology of Crohn’s disease and ulcerative colitis. Hum Pathol. 1975;6(1): 7–29. S0046-8177(75)80107-9 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Meisel JL, Ylvisaker T, et al. Rectal biopsy in the diagnosis of Crohn’s disease: value of multiple biopsies and serial sectioning. Gastroenterology. 1981;80(1):66–71. S0016508581000309 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Elliott EJ. Acute gastroenteritis in children. BMJ. 2007;334(7583):35–40. 334/7583/35 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–169. AJG1556 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn’s disease? Gut. 1989;30(9):1236–1240.
   PubMed Web of Science ®Google Scholar
• Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum. 2008;51(8):1283–1291. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817 e2–1826 e2. [pii][published Online First: Epub Date]|.
   Web of Science ®Google Scholar
• Burri E, Beglinger C, Lehmann FS. Monitoring of therapy for inflammatory bowel disease. Digestion. 2012;86(Suppl 1):1–5. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Newnham E, Hawkes E, Surender A, et al. Quantifying exposure to diagnostic medical radiation in patients with inflammatory bowel disease: are we contributing to malignancy? Aliment Pharmacol Ther. 2007;26(7):1019–1024. APT3449 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25(3):247–255. APT3184 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8(1):23–36. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27(9):793–798.
   PubMed Web of Science ®Google Scholar
• Montreuil J, Tonnelat J, Mullet S. Preparation and properties of lactosiderophilin (lactotransferrin) of human milk. Biochim Biophys Acta. 1960;45:413–421.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(11):1746–1754. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6): 524–534. 00054725-200606000-00013 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–431. 55/3/426 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Moussa R, Khashana A, Kamel N, et al. Fecal calprotectin levels in preterm infants with and without feeding intolerance. J Pediatr (Rio J). 2016;92(5):486–492. S0021-7557(16)30057-2 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am. 2012;41(2):483–495. S0889-8553(12)00008-8 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Piekkala M, Alfthan H, Merras-Salmio L, et al. Fecal calprotectin test performed at home - a prospective study of pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017. [published Online First: Epub Date]|. DOI:10.1097/MPG.0000000000001861.
   Web of Science ®Google Scholar
• Vinding KK, Elsberg H, Thorkilgaard T, et al. Fecal calprotectin measured by patients at home using smartphones–a new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(2):336–344. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52(6):847–853.
   PubMed Web of Science ®Google Scholar
• Yang Z, Tao T, Raftery MJ, et al. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol. 2001;69(6):986–994.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889–901. S0092-8674(00)80801-6 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn’s disease. Inflamm Bowel Dis. 2006;12(7):566–572. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Baynes RD, Bezwoda WR. Lactoferrin and the inflammatory response. Adv Exp Med Biol. 1994;357:133–141.
   PubMedGoogle Scholar
• Baveye S, Elass E, Mazurier J, et al. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999;37(3):281–286. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98(6):1309–1314. [published Online First: Epub Date]| [pii].
   PubMed Web of Science ®Google Scholar
• Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995;80(3):252–267.
   PubMed Web of Science ®Google Scholar
• Angriman I, Scarpa M, D’Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381(1):63–68. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48(1):48–54. 00005176-200901000-00008 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91(5):927–934.
   PubMed Web of Science ®Google Scholar
• Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13(11):1374–1378. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Walkowiak J, Banasiewicz T, Krokowicz P, et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005;40(12):1493–1494. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• McDowell G, Gupta S, Dellerba M, et al. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure. Ann Clin Biochem. 2004;41(Pt 6):491–493. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Oehler R, Weingartmann G, Manhart N, et al. Polytrauma induces increased expression of pyruvate kinase in neutrophils. Blood. 2000;95(3):1086–1092.
   PubMed Web of Science ®Google Scholar
• Hardt PD, Mazurek S, Toepler M, et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91(5):980–984. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Czub E, Herzig KH, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42(10):1147–1150. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117(4):814–822. S001650859900339X [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Annahazi A, Molnar T, Farkas K, et al. Fecal MMP-9: a new noninvasive differential diagnostic and activity marker in ulcerative colitis. Inflamm Bowel Dis. 2013;19(2):316–320. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Sipponen T, Valtonen E, et al. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2014;29(1):43–50. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Sipponen T, Valtonen E, et al. Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease. Int J Colorectal Dis. 2013. [published Online First: Epub Date]|. DOI:10.1007/s00384-013-1775-9.
   Web of Science ®Google Scholar
• Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570–1595. S0016-5085(08)00232-1 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Sc N, Chan FK, et al. An updated Asia Pacific consensus recommendations on colorectal cancer screening. Gut. 2015;64(1):121–132. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005;100(11):2519–2525. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35(9):642–647.
   PubMedGoogle Scholar
• Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J. 1998;45(1):69–73.
   PubMedGoogle Scholar
• Peterson CG, Eklund E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97(7):1755–1762. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Klass HJ, Neale G. Serum and faecal lysozyme in inflammatory bowel disease. Gut. 1978;19(3):233–239.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005;11(12):1085–1091. 00054725-200512000-00008 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• van der Sluys Veer A, Brouwer J, Biemond I, et al. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci. 1998;43(3):590–595.
   PubMed Web of Science ®Google Scholar
• Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol. 1992;27(2):139–142.
   PubMed Web of Science ®Google Scholar
• Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51(3–4):117–126.
   PubMed Web of Science ®Google Scholar
• Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19(5):1043–1052. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Hellstrom PM, Fagerhol MK, et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2(2):96–102. [pii][published Online First: Epub Date]|.
   PubMedGoogle Scholar
• Steigedal M, Marstad A, Haug M, et al. Lipocalin 2 imparts selective pressure on bacterial growth in the bladder and is elevated in women with urinary tract infection. J Immunol. 2014;193(12):6081–6089. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Kaur S, Guha S, et al. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012;1826(1):129–169. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432(7019):917–921. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18(2):407–413. ASN.2006080882 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Ostvik AE, Granlund AV, Torp SH, et al. Expression of toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2. Clin Exp Immunol. 2013;173(3):502–511. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Ronco C, Legrand M, Goldstein SL, et al. Neutrophil gelatinase-associated lipocalin: ready for routine clinical use? An international perspective. Blood Purif. 2014;37(4):271–285. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol. 1999;94(10):2923–2928. [published Online First: Epub Date]|.S0002927099004955 [pii].
   PubMed Web of Science ®Google Scholar
• Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med. 2017;6(11):99. E99 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15(8):1190–1198. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Diamanti A, Knafelz D, Panetta F, et al. Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn’s disease: preliminary report. Int J Colorectal Dis. 2011;26(11):1445–1451. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Henderson P, Anderson NH, Wilson DC. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(5):637–645. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Fall T, Mandic-Havelka A, Helmersson-Karlqvist J, et al. Reference intervals for fecal calprotectin in adults using two different extraction methods in the Uppsala-SCAPIS cohort. Clin Lab. 2017;63(9):1493–1496. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894–1899. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(5):669–673. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54(3):364–368. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Samant H, Desai D, Abraham P, et al. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease. Indian J Gastroenterol. 2015;34:431–435. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:221. [pii][published Online First: Epub Date]|. DOI:10.1186/1756-0500-2-221
   PubMedGoogle Scholar
• Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39(10):1017–1020. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Dai C, Jiang M, Sun MJ, et al. Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2018;33:990–997. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Tursi A, Elisei W, Picchio M, et al. Accuracy of rapid fecal calprotectin test in monitoring inflammatory bowel diseases under treatment with TNFalpha Antagonists. Dig Dis Sci. 2015;60(5):1406–1413. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104(3):673–678. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Chen JM, Liu T, Gao S, et al. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China. World J Gastroenterol. 2017;23(46):8235–8247. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• De Vos M, Dewit O, D’Haens G, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis. 2012;6(5):557–562. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Boon GJ, Day AS, Mulder CJ, et al. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol. 2015;21(40):11469–11480. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Bremner A, Roked S, Robinson R, et al. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94(12):1855–1858. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Canani RB, De Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42(1):9–15. 00005176-200601000-00007 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003;49(6 Pt 1):861–867.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Loof L, Merzoug RD, et al. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37(4):468–472.
   PubMed Web of Science ®Google Scholar
• D’Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103(8):2007–2014.
   PubMed Web of Science ®Google Scholar
• Steup WH, Brand A, Weterman IT, et al. The effect of perioperative blood transfusion on recurrence after primary operation for Crohn’s disease. Scand J Gastroenterol Suppl. 1991;188:81–86.
   PubMedGoogle Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–963. 0016-5085(90)90613-6 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10(1):17–22.
   PubMedGoogle Scholar
• Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96(6):663–674. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis. 2013;7:e641–e651. [published Online First: Epub Date]|. S1873-9946(13)00198-0 [pii].
   PubMedGoogle Scholar
• Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–872. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Scarpa M, D’Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum. 2007;50(6):861–869. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4(1):63–101. S1873-9946(09)00105-6 [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn’s disease. Inflamm Bowel Dis. 2014;20(6):978–986. [published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Kolho KL, Korpela K, Jaakkola T, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110(6):921–930. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104(34):13780–13785. [pii][publishedOnline First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Treem WR, Ahsan N, Shoup M, et al. Fecal short-chain fatty acids in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994;18(2):159–164.
   PubMed Web of Science ®Google Scholar
• Eeckhaut V, Machiels K, Perrier C, et al. Butyricicoccus pullicaecorum in inflammatory bowel disease. Gut. 2013;62(12):1745–1752. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Turroni F, Milani C, Duranti S, et al. Deciphering bifidobacterial-mediated metabolic interactions and their impact on gut microbiota by a multi-omics approach. ISME J. 2016;10(7):1656–1668. [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci. 1996;41(11):2254–2259.
   PubMed Web of Science ®Google Scholar
• Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology. 1992;103(1):51–56. 0016-5085(92)91094-K [pii][published Online First: Epub Date]|.
   PubMed Web of Science ®Google Scholar
• Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci. 1991;36(2):185–187.
   PubMed Web of Science ®Google Scholar